PD-L1

QR001, Rb

Artikelnummer:P001-H
Menge:
Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Spezies:Rabbit
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of the PD-L1 protein
Vorbehandlung:ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic, membranous
Kontrolle:Non-small cell lung cancer, tonsil
Synonyme:CD274, Programmed cell death 1 ligand 1, Programmed death ligand 1, PD-L1, PDCD1 ligand 1, B7 homolog 1, B7-H1.
Verfügbar in folgenden Ländern:worldwide
Beschreibung

Programmed Death Ligand 1 (PD-L1), also known as CD274 and B7-H1, is a transmembrane protein expressed on the surface of resting T-cells. Binding to its receptor PD-1, a T-cell immune checkpoint, T-cell activation is inhibited and autoimmune reaction is stopped. Some tumor cells use this mechanism to prevent apoptosis and obtain resistance against CD8+ T-cell mediated cell lysis. PD-L1 (QR001) is suitable to detect sentinel lymph node melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) as well as triple-negative breast cancer (TNBC).

Literatur

[1] Butte MJ, Pena-Cruz V et al. (2008). Mol Immunol. 45(13): 3567-72.
[2] Ostrand-Rosenberg S, Horn LA, Haile ST (2014). J Immunol. 193 (8): 3835-41.
[3] Freeman GJ, Long AJ et al. (2000). J Exp Med. 192(7): 1027-34.
[4] Sharpe AH, Wherry EJ et al. (2007). Nat Immunol. 8(3): 239-45.
[5] Patel SP, Kurzrock R (2015). Mol Cancer Ther. 14(4): 847-56.
[6] Büttner R, Gosney JR et al. (2017). J Clin Oncol. 35(34): 3867-76.
[7] Scheel AH, Baenfer G et al. (2017). Histopathology. doi: 10.1111/his.13375.
[8] Ghorani E, Kaur B et al. (2017). Lancet. 390: 2343-45. Supplementary appendix.
[9] Hofman P (2017). Expert Rev Mol Diagn. 17(12): 1097-1108.
[10] Menguy S, Prochazkova-Carlotti M et al. (2018). Am J Surg Pathol. 42(3): 326-34.
[11] 2017. Der Pathologe. 4: 345-50.
[12] Jöhrens K, Büttner R et al. QuIP Ring Trial Q1/2017.
[13] Lantuejoul S, Damotte D et al. (2019). J Thorac Dis. 11(Suppl 1): 89-101.
[14] Lantuejoul S, Adam J et al. (2018). Ann Pathol. 38(2): 110-25.
[15] Scimeca M, Bonfiglio R et al. (2019). Urol Oncol. pii: S1078-1439(19)30068-7.
[16] Bianchi A, Annibali O et al. (2019).

Kunden, die sich für diesen Artikel interessierten, interessierten sich auch für:

Kontakt